| Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes P Momtaz, CA O’Connor, JF Chou, M Capanu, W Park, C Bandlamudi, ... Cancer 127 (23), 4393-4402, 2021 | 28 | 2021 |
| Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice W Park, CA O'Connor, C Bandlamudi, D Forman, JF Chou, S Umeda, ... Clinical Cancer Research 28 (21), 4782-4792, 2022 | 13 | 2022 |
| Leptomeningeal disease in pancreas ductal adenocarcinoma: a manifestation of longevity CA O’Connor, JS Park, T Kaley, B Kezlarian, M Edelweiss, TJ Yang, ... Pancreatology 21 (3), 599-605, 2021 | 4 | 2021 |
| Pancreatic Cancer: BRCA Targeted Therapy and Beyond F Keane, CA O’Connor, W Park, T Seufferlein, EM O’Reilly Cancers 15 (11), 2955, 2023 | 3 | 2023 |
| A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ... Journal of Clinical Oncology 41 (4_suppl), 725-725, 2023 | 1 | 2023 |
| Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO). F Keane, F Balogun, C O'Connor, F Crowley, A Chan, D Cowzer, JF Chou, ... Journal of Clinical Oncology 41 (4_suppl), 685-685, 2023 | 1 | 2023 |
| Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC) W Park, C O'Connor, S Umeda, R Sharma, Y Zhu, ER Karnoub, ... Cancer Research 83 (7_Supplement), 6421-6421, 2023 | | 2023 |
| Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK). P Momtaz, CA O'Connor, JF Chou, M Capanu, KH Yu, AM Varghese, ... Journal of Clinical Oncology 38 (4_suppl), 708-708, 2020 | | 2020 |
